Toxicological assessment of a particulate yeast (1,3/1,6)-β-D-glucan in rats

被引:37
作者
Babicek, K.
Cechova, I.
Simon, R. R.
Harwood, M.
Cox, D. J.
机构
[1] BIOPHARM, Res Inst Biopharm & Vet Design, Jilove, Czech Republic
[2] Biothera Inc, Eagan, MN 55121 USA
关键词
(1,3)-beta-d-glucan; rat; toxicity; safety; yeast; NOAEL;
D O I
10.1016/j.fct.2007.03.013
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study investigates the toxicity of WGP((R)) 3-6, a yeast-derived P-glucan ingredient, during single-dose acute and sub-chronic toxicity studies in rats. For the acute study, Fisher-344 rats were administered WGPe 3-6 via gavage at a dose of 2000 mg/kg body weight, and any evidence of toxicity was monitored over a 14-day period. WGP((R)) 3-6 was well tolerated, indicating that the LD50 value is greater than 2000 mg/kg body weight. For the sub-chronic study, Fisher-344 rats (10/sex/group) were randomly allocated to receive daily gavage treatment with WGP((R)) 3-6 at doses of 0, 2,33.3, or 100 mg/kg body weight. Control and high-dose satellite recovery groups of each sex also were included. Full toxicological monitoring and endpoint investigations were performed throughout and upon completion of the study. No negative effects on animal weights or food consumption attributable to WGP((R)) 3-6 were evident at any dose. In addition, no mortality, clinical pathology, functional/behavioral, microscopic, or gross observations indicating toxicity were observed. Sporadic changes in some biochemical and hematological parameters were observed; however, since the effects were within the physiological ranges in historical controls, were not dose-responsive, or were not observed in both sexes, they were determined to be of no toxicological significance. In conclusion, no adverse or toxic effects were observed after subchronic oral administration of 2, 33.3, or 100 mg/kg body weight/day of WGP((R)) 3-6 in Fisher-344 rats, and therefore, a no observed adverse effect level (NOAEL) of 100 mg/kg body weight/day, the highest dose tested, was determined. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1719 / 1730
页数:12
相关论文
共 41 条
  • [1] RANDOMIZED PHASE I/II TRIAL OF A MACROPHAGE-SPECIFIC IMMUNOMODULATOR (PGG-GLUCAN) IN HIGH-RISK SURGICAL PATIENTS
    BABINEAU, TJ
    MARCELLO, P
    SWAILS, W
    KENLER, A
    BISTRIAN, B
    FORSE, RA
    [J]. ANNALS OF SURGERY, 1994, 220 (05) : 601 - 609
  • [2] BABINEAU TJ, 1994, ARCH SURG-CHICAGO, V129, P1204
  • [3] (1->3)-beta-D-glucans as biological response modifiers: A review of structure-functional activity relationships
    Bohn, JA
    BeMiller, JN
    [J]. CARBOHYDRATE POLYMERS, 1995, 28 (01) : 3 - 14
  • [4] A COMPARATIVE-EVALUATION OF PARTICULATE AND SOLUBLE GLUCAN IN AN ENDOTOXIN MODEL
    BOWERS, GJ
    PATCHEN, ML
    MACVITTIE, TJ
    HIRSCH, EF
    FINK, MP
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (03): : 313 - 321
  • [5] Soluble β-1,3/1,6-glucan from yeast inhibits experimental periodontal disease in Wistar rats
    Breivik, T
    Opstad, PK
    Engstad, R
    Gundersen, G
    Gjermo, P
    Preus, H
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 2005, 32 (04) : 347 - 352
  • [6] BROWDER W, 1990, ANN SURG, V211, P605
  • [7] HEMATOLOGY TESTS IN TOXICOLOGY - TIME FOR A RE-THINK
    BROWN, G
    [J]. COMPARATIVE HAEMATOLOGY INTERNATIONAL, 1992, 2 (04): : 231 - 235
  • [8] Dectin-1 mediates the biological effects of β-glucans
    Brown, GD
    Herre, J
    Williams, DL
    Willment, JA
    Marshall, ASJ
    Gordon, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (09) : 1119 - 1124
  • [9] Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies
    Cheung, NKV
    Modak, S
    Vickers, A
    Knuckles, B
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (10) : 557 - 564
  • [10] Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis
    Cisneros, RL
    Gibson, FC
    Tzianabos, AO
    [J]. INFECTION AND IMMUNITY, 1996, 64 (06) : 2201 - 2205